Lamond David's Form 4 filing
Quince Therapeutics, Inc. (QNCX) · filed Aug 31, 2023
- Accession no.
- 0001209191-23-047880
- Filed
- Aug 31, 2023
- Trade date
- Aug 30-31, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $107.9K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lamond DavidCIK 0001770790 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 30, 2023 | Common Stock | PPurchaseAcquired | +41,026 | $1.31 | +$53,744.06 | 2,138,135 | Indirect | |
| Aug 31, 2023 | Common Stock | PPurchaseAcquired | +41,026 | $1.32 | +$54,154.32 | 2,179,161 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.